Valuation: Sanofi

Market Cap 91.8B 104B 85.28B 78.43B 147B 10,108B 150B 1,020B 398B 4,930B 392B 383B 17,104B P/E 2026 *
11.5x
P/E 2027 * 10.6x
Enterprise Value 101B 115B 94.22B 86.66B 163B 11,168B 165B 1,127B 439B 5,447B 433B 424B 18,898B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 1.94x
Free-Float
89%
Yield 2026 *
5.57%
Yield 2027 * 5.9%
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer 51 11/09/2023
Director TitleAgeSince
Director/Board Member 60 30/04/2019
Director/Board Member 57 28/04/2020
Director/Board Member 64 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 105B
+1.97%+1.43%+48.44%+158.18% 1,037B
+1.42%+3.72%+53.32%+51.55% 615B
+1.43%+0.99%+34.83%+79.44% 448B
+5.14%+5.84%+37.54%+27.28% 326B
+1.85%+4.64%+38.53%+39.87% 293B
-0.11%+0.97%+22.57%+17.81% 264B
+0.25%-3.10%-24.44%-42.25% 216B
+1.49%-0.02%+20.14%+57.80% 198B
+0.40%-3.99%+15.23%+68.50% 162B
Average +1.43%+1.12%+27.35%+50.91% 395.27B
Weighted average by Cap. +1.55%+1.47%+36.34%+75.89%

Financials

2026 *2027 *
Net sales 46.94B 53.38B 43.61B 40.11B 75.22B 5,169B 76.57B 521B 203B 2,521B 200B 196B 8,747B 50.04B 56.89B 46.49B 42.75B 80.18B 5,510B 81.61B 556B 217B 2,687B 214B 209B 9,323B
Net income 8.33B 9.47B 7.74B 7.12B 13.35B 917B 13.59B 92.55B 36.1B 447B 35.56B 34.79B 1,552B 9.22B 10.49B 8.57B 7.88B 14.78B 1,016B 15.05B 102B 39.97B 495B 39.37B 38.52B 1,719B
Net Debt 9.63B 10.95B 8.95B 8.23B 15.43B 1,061B 15.71B 107B 41.73B 517B 41.11B 40.22B 1,795B 5.52B 6.28B 5.13B 4.72B 8.84B 608B 9B 61.31B 23.92B 296B 23.56B 23.05B 1,028B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
76.36EUR
Average target price
95.60EUR
Spread / Average Target
+25.20%

Quarterly revenue - Rate of surprise